10-K: Simulations Plus Reports Significant Loss, Impairments in FY25

Simulations Plus, Inc. reported a net loss of $64.7 million for fiscal year 2025, primarily driven by $77.2 million in impairment charges related to underperforming acquisitions and a stock price decline.

Summary

• A net loss of $64.7 million was reported for fiscal year 2025, a significant reversal from net income of $9.954 million in fiscal year 2024.
• Total revenues increased by 13% to $79.179 million for fiscal year 2025, up from $70.013 million in fiscal year 2024, primarily driven by the Pro-ficiency acquisition.
• Gross profit increased by 7% to $46.221 million in fiscal year 2025, but the gross margin percentage declined to 58% from 62% in fiscal year 2024, largely due to the underperformance of Pro-ficiency.
• Operating expenses surged by 216% to $116.950 million in fiscal year 2025, predominantly due to $77.221 million in impairment charges.
• Impairment charges of $77.221 million were recorded in fiscal year 2025, including $51.632 million for goodwill and $25.589 million for other intangibles and long-lived assets, primarily stemming from the Pro-ficiency acquisition.
• Research and development (expensed) increased by 20% to $6.884 million in fiscal year 2025.
• Sales and marketing expenses rose by 34% to $11.904 million in fiscal year 2025.
• General and administrative expenses decreased by 6% to $20.941 million in fiscal year 2025, despite a $0.7 million reorganization expense and $0.4 million office space restructuring costs, offset by a $2.7 million decrease in M&A expense.
• Other income, net, decreased by 78% to $1.352 million in fiscal year 2025, mainly due to lower interest income and a decrease in the fair value of the Immunetrics earnout liability.
• The effective tax rate decreased to 7% in fiscal year 2025 from 20% in fiscal year 2024, primarily due to the permanent item associated with the non-deductible goodwill impairment.
• The company reorganized its internal structure in the fourth quarter of fiscal year 2025 to a function-based operating platform, shifting from business units to Services, Operations, Product and Technology, Research and Development, Sales and Marketing, and General and Administrative.
• Four office locations were exited, and the headquarters moved to Research Triangle Park, NC, as part of a plan to reduce excess office space and carbon footprint.
• A 10% workforce reduction was implemented through the 2025 Restructuring Plan, incurring $0.7 million in severance costs and expected to reduce operating expenses by approximately $4.3 million annually.
• Quarterly cash dividends were discontinued after the August 5, 2024 distribution, with funds reallocated to growth initiatives.
• $30 million remains available for additional share repurchases under the authorized program, but no repurchases were made in fiscal years 2025 or 2024.
• A $1.0 million unsecured and subordinated convertible promissory note was issued to Nurocor, Inc. in July 2025.

Sentiment

Score: 3

Explanation: The company experienced a substantial net loss in fiscal year 2025 primarily due to significant impairment charges related to underperforming acquisitions and a stock price decline. While revenue grew, gross margin decreased, and the discontinuation of dividends signals a shift in capital allocation strategy. The workforce reduction and auditor changes also add to a negative sentiment, indicating significant financial distress and uncertainty.

Positives

• Total revenues increased by 13% to $79.179 million in fiscal year 2025.
• Software revenue grew to $45.828 million in fiscal year 2025 from $41.024 million in fiscal year 2024.
• Services revenue grew to $33.351 million in fiscal year 2025 from $28.989 million in fiscal year 2024.
• A strong cash position was maintained with $30.853 million in cash and cash equivalents as of August 31, 2025.
• Net cash provided by operating activities increased to $18.126 million in fiscal year 2025 from $13.320 million in fiscal year 2024.
• Successful release of ADMET Predictor Version 13 in June 2025 and GastroPlus Version 10.2 in September 2025, adding new features and AI/automation functionality.
• Strategic collaborations, including validation of ADMET Predictor models with IMB PAS and development of new AI drug discovery offering with USC, enhance product capabilities.
• Reorganization of internal structure aims for a more integrated and cohesive operating platform.
• Workforce reduction is expected to reduce operating expenses by $4.3 million annually.
• Commitment to ESG initiatives, including a 75% reduction in energy usage compared to the prior year by consolidating servers.
• High employee retention with voluntary turnover under 6% in fiscal year 2024.
• Recognized for workplace culture (Best Company for Diversity, Women, Leadership, Benefits in 2025 by Comparably).

Negatives

• A net loss of $64.718 million was reported in fiscal year 2025, a significant reversal from net income in prior years.
• Impairment charges of $77.221 million were recorded in fiscal year 2025, primarily due to the underperformance of the Pro-ficiency acquisition and a significant stock price decline.
• Gross margin percentage declined to 58% in fiscal year 2025 from 62% in fiscal year 2024, largely attributable to the underperformance of Pro-ficiency revenues.
• Total operating expenses increased significantly by 216% due to the substantial impairment charges.
• Other income, net, decreased by $4.928 million (78%) in fiscal year 2025, mainly due to lower interest income.
• The company discontinued quarterly cash dividends after August 5, 2024.
• The underperformance of the Pro-ficiency acquisition led to significant impairment charges.
• The company experienced two changes in its independent registered public accounting firm within the fiscal year (RSJ to Grant Thornton, then back to RSJ), with Grant Thornton disagreeing with the company's statements regarding the change.

Risks

• Ability to sustain or increase revenues depends on success in entering new markets and expanding existing client use.
• A decrease in, or resistance to, the acceptance of model-informed drug development by regulatory authorities or academic institutions could reduce demand for products and services.
• Increasing competition and costs within the pharmaceutical and biotechnology industries may affect demand for products and services.
• Health care reform and restrictions on reimbursement may reduce R&D expenditures by clients.
• Strong competition in the life science market for modeling and simulation software and cheminformatics products, including from larger companies, in-house development, and open-source initiatives.
• Rapid advances in AI and ML could enable new or existing competitors to automate aspects of modeling, simulation, or data analysis, reducing demand if the company does not innovate at the same pace.
• Subject to price pressures in competitive markets, which could adversely affect revenues and earnings.
• Insurance coverage may be insufficient, or unavailable in the future.
• Negative commentaries by regulatory agencies or failure to comply with regulations could harm reputation and operating results.
• Lengthy sales cycle and potential delays or cancellations of client contracts could negatively impact revenue.
• Fixed-price contracts bear financial risk if underpriced or cost estimates are overrun, potentially resulting in losses.
• Impairment of goodwill or intangible assets may adversely impact future results of operations (already occurred in fiscal year 2025).
• Delays in the release of new or enhanced products or services or undetected errors could result in increased costs, delayed market acceptance, and lost revenue.
• Various risks associated with global business operations, including local economic conditions, currency-exchange-rate fluctuations, political changes, and compliance with foreign laws.
• Changes in U.S. and international tax laws or regulations and resolution of tax disputes could negatively affect financial results.
• Contract research services create a risk of liability for errors or omissions.
• The drug discovery and development industry has a history of patent and other intellectual property litigation, which can be costly.
• Inability to successfully develop and market new services and products.
• Dependence on key personnel and potential inability to retain or recruit qualified staff.
• Risks associated with selecting and integrating acquired businesses and technologies, or managing divestitures.
• Quarterly and annual operating results fluctuate and may continue to fluctuate.
• Exposure to foreign currency exchange rate risk due to international operations.
• Client cancellations, terminations, or delays in clinical trials could adversely impact business.
• Security breaches could disrupt business, harm operating results, and deter clients.
• Changes in and/or failure to comply with applicable data privacy laws, regulations, and interpretations (HIPAA, GDPR, PIPL, CCPA, CPRA, etc.).
• Reliance on a single internal hosting facility and Amazon Web Services (AWS) for solutions, with potential disruptions harming business.
• Defects or errors in software applications could harm reputation, result in significant cost, and impair marketing ability.
• Inability to reliably meet data storage and management requirements or service interruptions over the Internet could harm client satisfaction and reputation.
• Use of open-source software carries risks of non-compliance with license terms, potentially affecting intellectual property.
• Inability to adequately enforce or defend intellectual property and other proprietary rights.
• Current and future litigation could be costly and time-consuming.
• Substantial costs from product liability claims.
• A downturn in the clinical trial market could decrease revenues.
• Failure to maintain proper and effective internal control over financial reporting as business expands.
• Volatility in common stock price due to various factors.
• Issuance of common stock, convertible debt, or equity-linked securities could result in dilution.
• The share repurchase program may not be fully consummated or enhance long-term shareholder value, and could increase stock price volatility.
• The use of AI in products and services may result in reputational and competitive harm, and legal/regulatory risks due to the evolving landscape.
• Interruption or termination of government cash grants could adversely impact business.
• A federal government shutdown could delay or suspend grant awards, renewals, or reimbursements, and disrupt client projects.
• Changes in government regulation, funding, or practices relating to pharmaceutical/biotechnology industries could decrease demand for services.

Future Outlook

The company expects existing cash, cash equivalents, short-term investments, cash generated by ongoing operations, and working capital to be sufficient to fund operating activities and material capital expenditures for the next 12 months and beyond. It intends to continue offering regular updates to products and expanding its existing suite of products and services. Management plans to place greater emphasis on identifying and growing future leaders by strengthening leadership development and succession planning in the coming year. The 2025 Restructuring Plan is expected to reduce operating expenses by approximately $4.3 million on an annualized basis. The company will also continue to evaluate its ESG disclosures as regulatory expectations evolve and seeks opportunities for strategic acquisitions, investments, and partnerships.

Management Comments

• "Our mission is to create value for our clients by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives."
• "The Company reorganized its internal structure to create a more integrated and cohesive operating platform based on product and service solutions."
• "During the fourth quarter of fiscal year 2025, the Company pivoted to an account-based solution selling business model, where the focus is on identifying and solving client pain points across the drug development lifecycle rather than selling discrete products or services."
• "We believe that we are strategically positioned to offer competitive modeling and simulation consulting services to companies."
• "Our continued success depends on attracting and retaining top talent."
• "Our Board of Directors has determined to suspend the quarterly dividends that we have historically paid to holders of our common stock and to use those funds to invest more into our business instead."
• "Management believes that there is no pending or threatened litigation to which the Company and any of its subsidiaries... would have a material adverse effect on our business, results of operations, financial condition and/or cash flows."
• "As of the date of this Report, we are not aware of any cybersecurity incidents... that have had or are reasonably likely to have a material impact on the Company's results of operations or financial condition."

Industry Context

The biopharma sector faces significant challenges with drug development being time-consuming and expensive, averaging 10-15 years and $2.2 billion per drug. The company's model-informed drug development (MIDD) solutions aim to address these issues by accelerating timelines and reducing costs. Regulatory agencies globally are increasingly recognizing and encouraging the use of modeling and simulation, which positively impacts the company's business. The market is highly competitive, with rapid advancements in AI and machine learning necessitating continuous innovation. Healthcare reform and cost containment efforts by governments and third-party payers can pressure R&D spending in the pharmaceutical industry, potentially affecting demand for the company's offerings. The company's remote-first work culture and office consolidation reflect broader industry trends towards flexible work and reduced physical footprints.

Comparison to Industry Standards

• The company's MIDD software and services aim to accelerate drug development and reduce R&D costs, addressing the industry benchmark of 10-15 years and $2.2 billion average cost to develop a single drug.
• DILIsym is described as the 'most widely used software for DILI prediction' and is utilized by the FDA's DILI team, indicating a leading position in quantitative systems toxicology.
• ADMET Predictor is highlighted as a 'top-ranked, chemistry-based computer program,' suggesting strong competitive standing in AI/ML-driven property prediction.
• The company believes it is an 'industry leader in providing strong client training and technical support' for its modeling and simulation products.
• Competitors in the life science market for modeling and simulation software and cheminformatics products include Optibrium, Certara, ICON, Metrum Research Group, Veeva, and WCG, some of whom have larger resources.

Corporate Governance

Legal Proceedings

• The company is not a party to any legal proceedings and is not aware of any pending or threatened legal proceedings of any kind that would have a material adverse effect on its business, results of operations, financial condition, and/or cash flows.

Related Party Transactions

• Information regarding related party transactions is incorporated by reference from the company's definitive proxy statement for the 2026 Annual Meeting of Shareholders.

Stakeholder Impact

• Shareholders: Negative impact due to a significant net loss, substantial impairment charges, decline in gross margin, discontinuation of dividends, and potential dilution from future capital raises. Stock price volatility is a risk.
• Employees: A workforce reduction of approximately 10% occurred due to restructuring. Positive aspects include a remote-first culture, paid parental leave, wellness programs, and recognition for workplace culture.
• Customers/Clients: Continued focus on enhancing drug discovery and development, clinical trial operations, and commercialization through software and consulting services. New product releases (ADMET Predictor V13, GastroPlus V10.2) and collaborations aim to improve offerings.
• Creditors: Liquidity appears sufficient for the next 12 months, but significant losses and potential future capital raises could be a factor in credit assessment.
• Regulatory Authorities: The company's products are used to comply with regulatory guidance, and the company is subject to evolving data privacy and AI regulations.

Next Steps

• File the definitive proxy statement for the 2026 Annual Meeting of Shareholders within 120 days after August 31, 2025.
• Continue to offer regular updates to products and expand the existing suite of products and services.
• Place greater emphasis on identifying and growing future leaders by strengthening leadership development and succession planning in the coming year.
• Evaluate ESG disclosures as regulatory expectations evolve.
• Potentially pursue strategic acquisitions, investments, and partnerships.
• Potentially repurchase up to $30 million more of common stock under the authorized program.

Key Dates

Recommendation

The company reported a substantial net loss of $64.7 million for fiscal year 2025, primarily driven by $77.2 million in impairment charges related to underperforming acquisitions (notably Pro-ficiency) and a significant stock price decline. This indicates poor capital allocation and integration challenges. While revenue grew, the gross margin percentage declined, and the discontinuation of quarterly dividends signals a shift away from shareholder returns in the short to medium term. The double change in auditors within the fiscal year, with one auditor disagreeing with the company's statements, raises corporate governance concerns. The 10% workforce reduction, while aimed at efficiency, reflects underlying operational issues. These factors collectively point to significant financial distress and uncertainty, making the stock a 'Sell' for a seasoned investor.

Keywords

Biopharma, Drug Discovery, Drug Development, Clinical Trials, Biosimulation, AI, Machine Learning, PBPK, QSP, QST, ADMET Predictor, GastroPlus, MonolixSuite, Pro-ficiency, SEC Filing, 10-K, Financial Results, Impairment, Software, Consulting Services, Healthcare Technology